Clinical trial
Tanespimycin in Treating Patients With Stage III-IV Melanoma
NCT00087386 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00087386 |
|---|---|
| Title | Tanespimycin in Treating Patients With Stage III-IV Melanoma |
| Official title | Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2007 |
| First posted | Jul 12, 2004 |
| Last update posted | Apr 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: